Patent ID: 6576231
Filing Date: 2003-06-10
Classification: A61K,Y10S

Abstract:
A method for treating an HLV-infected patient consisting of administering a combination of one protease inhibitor selected from the group consisting of indinavir, nelfinavir, ritonavir and saquinavir, at least one additional antiretroviral agent that is selected from the group consisting of didanosine, lamivudine, stavudine, dalcitabine and a non-nucleoside reverse transcriptase inhibitor, and human recombinant GM-CSF, wherein said combination is administered for a time sufficient to induce an increase of at least 30% in the patient's CD4+ T-lymphocyte count, and further wherein said patient has received indinavir, nelfinavir, ritonavir or saquinavir for a minimum of eight weeks prior to receiving a first dose of GM-CSF.